E2F transcription factor 1 overexpression as a poor prognostic factor in patients with nasopharyngeal carcinomas

Chien Feng Li, Li Tzong Chen, Ching Yih Lin, Hsuan Ying Huang, Chung Hsi Hsing, Chiang Ting Huang, Yow Ling Shiue

Research output: Contribution to journalArticle

Abstract

Nasopharyngeal carcinoma (NPC) is an endemic head and neck epithelial malignancy in Southeastern Asia and Taiwan. The E2 factor (E2F) family of transcription factors is downstream targets of the retinoblastoma protein 1. The E2F family of transcription factors is the key regulator of genes involved in cell cycle progression, cell fate determination, DNA damage repair and apoptosis. E2F1 is unique in that it contributes both to the control of cellular proliferation and cellular death. However, the expression of E2F1 protein and its clinicopathological associations in patients with NPC are yet to be evaluated. Immunoexpression of E2F1 was retrospectively assessed in biopsies of 124 consecutive NPC patients without initial distant metastasis and treated with consistent guidelines. The outcomes were correlated with clinicopathological features and patient survivals. Results indicated that high E2F1 protein level (50%) was correlated with primary tumor (pth American Joint Committee on Cancer). In multivariate analyses, high E2F1 expression emerged as an independent prognosticator for worse disease-specific survival (p=0.003), distal metastasis-free survival (p=0.003), and local recurrence-free survival (p=0.039). In conclusion, high E2F1 protein level is common, associated with adverse prognosticators, and might confer tumor aggressiveness through tumor cell proliferation and metastasis.

Original languageEnglish
Pages (from-to)23-30
Number of pages8
JournalBiomarkers and Genomic Medicine
Volume5
Issue number1-2
DOIs
Publication statusPublished - 2013

    Fingerprint

Keywords

  • E2F transcription factor 1
  • Nasopharyngeal carcinoma
  • Survival

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biomedical Engineering
  • Medicine(all)
  • Drug Discovery

Cite this